Alatrofloxacin: Difference between revisions
Appearance
Content deleted Content added
Ozzie10aaaa (talk | contribs) m Cleaned up using AutoEd |
|||
(7 intermediate revisions by 7 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{ref improve|date=August 2014}} |
{{ref improve|date=August 2014}} |
||
{{Drugbox |
{{Drugbox |
||
Line 9: | Line 10: | ||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = |
| tradename = |
||
| Drugs.com = {{drugs.com|CONS|alatrofloxacin}} |
| Drugs.com = {{drugs.com|CONS|alatrofloxacin}} |
||
| MedlinePlus = a605016 |
| MedlinePlus = a605016 |
||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
||
| pregnancy_US = C |
| pregnancy_US = C |
||
| pregnancy_category = |
| pregnancy_category = |
||
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
||
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
||
Line 33: | Line 34: | ||
| CAS_number = 146961-76-4 |
| CAS_number = 146961-76-4 |
||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = |
| DrugBank = |
||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = 21243647 |
| ChemSpiderID = 21243647 |
||
Line 44: | Line 45: | ||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=26 | H=25 | F=3 | N=6 | O=5 |
| C=26 | H=25 | F=3 | N=6 | O=5 |
||
| molecular_weight = 558.509 g/mol |
|||
| smiles = C[C@@H](C(=O)N[C@@H](C)C(=O)N[C@H]1[C@H]2[C@@H]1CN(C2)C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F)N |
| smiles = C[C@@H](C(=O)N[C@@H](C)C(=O)N[C@H]1[C@H]2[C@@H]1CN(C2)C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F)N |
||
Line 54: | Line 54: | ||
}} |
}} |
||
'''Alatrofloxacin''' ('''Trovan IV''') is a [[fluoroquinolone antibiotic]] developed by [[Pfizer]], delivered as a [[mesylate]] [[salt (chemistry)|salt]].<ref>{{cite web|title=Center for Drug Evaluation and Research {{ndash}} Application Number: 020759/020760 {{ndash}} Chemistry Review(s)|publisher=[[Food and Drug Administration]]|url=http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a_chemr.pdf| |
'''Alatrofloxacin''' ('''Trovan IV''') is a [[fluoroquinolone antibiotic]] developed by [[Pfizer]], delivered as a [[mesylate]] [[salt (chemistry)|salt]].<ref>{{cite web|title=Center for Drug Evaluation and Research {{ndash}} Application Number: 020759/020760 {{ndash}} Chemistry Review(s)|publisher=[[Food and Drug Administration]]|url=http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a_chemr.pdf|access-date=29 August 2014}}</ref> |
||
[[Trovafloxacin]] and alatrofloxacin were both withdrawn from the U.S. market in June 2006 due to [[hepatotoxicity]] leading to liver transplant or death.<ref>{{cite journal | vauthors = Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL | title = Market withdrawal of new molecular entities approved in the United States from 1980 to 2009 | journal = Pharmacoepidemiology and Drug Safety | volume = 20 | issue = 7 | pages = 772–777 | date = July 2011 | pmid = 21574210 | doi = 10.1002/pds.2155 | s2cid = 23821961 }}</ref> |
|||
Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in June of 2006. |
|||
==See also== |
== See also == |
||
* [[Fluoroquinolones]] |
* [[Fluoroquinolones]] |
||
==References== |
== References == |
||
{{Reflist}} |
|||
<references /> |
|||
{{QuinoloneAntiBiotics}} |
{{QuinoloneAntiBiotics}} |
||
Line 72: | Line 72: | ||
[[Category:Naphthyridines]] |
[[Category:Naphthyridines]] |
||
[[Category:Carboxylic acids]] |
[[Category:Carboxylic acids]] |
||
{{antibiotic-stub}} |
{{antibiotic-stub}} |
Latest revision as of 01:55, 31 December 2022
This article needs additional citations for verification. (August 2014) |
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a605016 |
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | N/A |
Protein binding | 76% (trovafloxacin) |
Metabolism | Quickly hydrolyzed to trovafloxacin |
Elimination half-life | 9 to 12 hours (trovafloxacin) |
Excretion | Fecal and renal (trovafloxacin) |
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H25F3N6O5 |
Molar mass | 558.518 g·mol−1 |
3D model (JSmol) | |
| |
| |
|
Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt.[1]
Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in June 2006 due to hepatotoxicity leading to liver transplant or death.[2]
See also[edit]
References[edit]
- ^ "Center for Drug Evaluation and Research – Application Number: 020759/020760 – Chemistry Review(s)" (PDF). Food and Drug Administration. Retrieved 29 August 2014.
- ^ Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL (July 2011). "Market withdrawal of new molecular entities approved in the United States from 1980 to 2009". Pharmacoepidemiology and Drug Safety. 20 (7): 772–777. doi:10.1002/pds.2155. PMID 21574210. S2CID 23821961.